Press release
KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit
– Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment - – When provided similar
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment -\n\n\n– When provided similar efficacy and safety profiles for oral and injectable on-demand treatments for HAE attacks, adults and adolescents express a strong preference for oral on-demand treatment –\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented data on the hereditary angioedema (HAE) attack journey and a patient preference study at the 2023 US HAEA National Summit in Orlando, Florida.\n\n\nThe following presentations occurred at the HAEA Summit:\n\n\n\nIn Their Own Words - Patient Descriptions of the Earliest Recognition of HAE Attack Onset: Michael E. Manning, Allergy, Asthma & Immunology Associates, Ltd., Internal Medicine, UA College of Medicine-Phoenix, Scottsdale, Arizona, United States (Poster presentation)\n\n\n\nRecognizing the Importance of Early On-Demand Treatment in the HAE Attack Journey: Michael E. Manning (presenter only), Allergy, Asthma & Immunology Associates, Ltd., Internal Medicine, UA College of Medicine-Phoenix, Scottsdale, Arizona, United States (Poster presentation)\n\n\n\nPreferences of People with Hereditary Angioedema for On-Demand Treatment: A US-Based Qualitative Study: Paula J. Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster presentation)\n\n\n\n“The data presented at HAEA adds to the growing evidence that there remains an important unmet need for both people using only on-demand therapies as well as those on long-term prophylaxis,” said Andrew Crockett, Chief Executive Officer of KalVista. “People living with HAE clearly recognize the start of their HAE attacks and understand that they should treat them as early as possible to enable return to normal activities, yet often delay or deny themselves treatment due to the many challenges associated with injection or infusions. The data shows that these challenges impact prophylaxis users, many of whom still suffer from breakthrough attacks, as much as those who use only on-demand medications. By offering the first oral...